TRIMTECH Therapeutics
Latest round
- Seed
Last raised
- Feb 2026
Total raised
- $48M
Investors
- 11
About TRIMTECH Therapeutics
Founded in 2023 in Cambridge, UK, TRIMTECH Therapeutics Limited specializes in biotherapeutics targeting protein aggregation disorders. Trimtech Therapeutics specializes in the development of a distinctive portfolio of therapeutic agents aimed at treating central nervous system (CNS) and inflammatory disorders. The company's core offerings, known as TRIMTACs™ and TRIMGLUEs™, are designed to selectively target and eliminate disease-causing protein aggregates. This innovative approach harnesses the potential of TRIM21, a ubiquitin ligase that the company has identified as an underutilized but widely expressed target in the treatment of protein aggregation disorders. The primary end-users of these therapeutic solutions are patients suffering from intractable CNS conditions and inflammatory diseases. Trimtech Therapeutics is focused on delivering its products in key global markets, including North America, Europe, and parts of Asia, thereby addressing a diverse client base that spans healthcare providers, research institutions, and pharmaceutical companies. The company's revenue structure is based on partnerships with pharmaceutical companies and research institutions, allowing for collaborative development and commercialization of its proprietary technologies. Transactions are expected to occur through B2B partnerships, wherein Trimtech collaborates with larger pharmaceutical firms to integrate its TRIMTACs™ and TRIMGLUEs™ into broader therapeutic frameworks. Revenue generation is further supported by potential licensing agreements and milestone payments tied to the development stages of its products. These agreements typically revolve around the successful advancement of therapeutic candidates through clinical trials, ultimately driving value creation for both Trimtech and its partners.
Who invested in TRIMTECH Therapeutics
11 investors across 2 rounds
See all investors in TRIMTECH Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about TRIMTECH Therapeutics
Who invested in TRIMTECH Therapeutics?
TRIMTECH Therapeutics has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TRIMTECH Therapeutics raised?
TRIMTECH Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did TRIMTECH Therapeutics last raise money?
TRIMTECH Therapeutics's most recent round on record is a Seed, in Feb 2026.
What does TRIMTECH Therapeutics do?
Founded in 2023 in Cambridge, UK, TRIMTECH Therapeutics Limited specializes in biotherapeutics targeting protein aggregation disorders.
Where is TRIMTECH Therapeutics headquartered?
TRIMTECH Therapeutics is headquartered in Cambridge, UK.
Which VCs invest in companies like TRIMTECH Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at TRIMTECH Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like TRIMTECH Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.